# High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Central Nervous System Lymphoma

> **NCT06625359** · PHASE2 · TERMINATED · sponsor: **Seoul National University Hospital** · enrollment: 17 (actual)

## Conditions studied

- Central Nervous System Lymphoma

## Interventions

- **DRUG:** Thiotepa in conditioning before transplantation

## Key facts

- **NCT ID:** NCT06625359
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06-01
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** slow enrollment
- **Last updated:** 2024-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06625359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06625359, "High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06625359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*